For how we live.
A Cochrane review of 11 trials found flight stockings sharply cut silent deep-vein clots. But across nearly 2,900 passengers, the trials recorded no pulmonary embolism, death, or symptomatic clot at all.
Two Cochrane reviews back scopolamine and first-generation antihistamines for preventing motion sickness. Both found the same gap: not a single randomised trial has looked at relieving symptoms already under way.
Expert guidelines back antibiotics for moderate-to-severe cases and simple measures for mild ones. The popular Pepto-Bismol prevention habit rests on 1980s data — and a 2025 trial could not confirm it worked.
A Cochrane review of 64 trials found acetazolamide cut the risk of acute mountain sickness by about half. It is a genuine drug effect, not a folk remedy — and it is a prescription decision, not a supplement.
A Cochrane review found melatonin reduced jet lag in nine of ten trials. Sleep medicine's own guideline rates it a first-tier option for jet lag disorder. Take it at the wrong hour and it can make things worse.
A CDC surveillance summary puts 2024 at 359% above the 2010–2023 annual average. The 2.8% that were locally acquired are the part that changes what mosquito control has to plan for.
Nineteen MERS cases were reported worldwide in 2025, seventeen of them in Saudi Arabia. The two in France are the first infections detected outside the region in six years.